Flu Vaccine Plus GLA-SE 17. Stoute JA, Heppner DG, Jr., Mason CJ, Siangla J, Opollo MO, et al. (2006) Phase 1 safety and immunogenicity trial of malaria vaccine RTS,S/AS02A in adults in a hyperendemic region of western Kenya. Am J Trop Med Hyg 75: 166–170. 18. Weksler ME, Szabo P (2000) The effect of age on the B-cell repertoire. J Clin Immunol 20: 240–249. 19. Deng Y, Jing Y, Campbell AE, Gravenstein S (2004) Age-related impaired type 1 T cell responses to influenza: reduced activation ex vivo, decreased expansion in CTL culture in vitro, and blunted response to influenza vaccination in vivo in the elderly. J Immunol 172: 3437–3446. 20. Baudner BC, Ronconi V, Casini D, Tortoli M, Kazzaz J, et al. (2009) MF59 emulsion is an effective delivery system for a synthetic TLR4 agonist (E6020). Pharm Res 26: 1477–1485. 21. Baumgarth N, Kelso A (1996) In vivo blockade of gamma interferon affects the influenza virus-induced humoral and the local cellular immune response in lung tissue. J Virol 70: 4411–4418. 22. Belz GT, Wodarz D, Diaz G, Nowak MA, Doherty PC (2002) Compromised influenza virus-specific CD8(+)-T-cell memory in CD4(+)-T-cell-deficient mice. J Virol 76: 12388–12393. 23. Brown DM, Roman E, Swain SL (2004) CD4 T cell responses to influenza infection. Semin Immunol 16: 171–177. 24. Wong GH, Goeddel DV (1986) Tumour necrosis factors alpha and beta inhibit virus replication and synergize with interferons. Nature 323: 819–822. 25. Mbawuike IN, Acuna C, Caballero D, Pham-Nguyen K, Gilbert B, et al. (1996) Reversal of age-related deficient influenza virus-specific CTL responses and IFN-gamma production by monophosphoryl lipid A. Cell Immunol 173: 64–78. 26. Singh M, Carlson JR, Briones M, Ugozzoli M, Kazzaz J, et al. (1998) A comparison of biodegradable microparticles and MF59 as systemic adjuvants for recombinant gD from HSV-2. Vaccine 16: 1822–1827. 27. Doherty PC, Topham DJ, Tripp RA, Cardin RD, Brooks JW, et al. (1997) Effector CD4+ and CD8+ T-cell mechanisms in the control of respiratory virus infections. Immunol Rev 159: 105–117. 28. Anderson RC, Fox CB, Dutill TS, Shaverdian N, Evers TL, et al. (2010) Physicochemical characterization and biological activity of synthetic TLR4 agonist formulations. Colloids Surf B Biointerfaces 75: 123–132. 29. Draize JH (1959) Appraisal of the Safety of Chemicals in Foods, Drug and Cosmetics. AustinTexas: Texas State Department of Health. 30. Lu X, Clements JD, Katz JM (2002) Mutant Escherichia coli heat-labile enterotoxin [LT(R192G)] enhances protective humoral and cellular immune responses to orally administered inactivated influenza vaccine. Vaccine 20: 1019–1029. 31. Kendal AP SJ, Pereira MS (1982) In: Concepts and procedures for laboratory- based influenza surveillance. Atlanta: CDC. pp B17–35. PLoS ONE | www.plosone.org 11 October 2010 | Volume 5 | Issue 10 | e13677